Drug Approvals

Celgene wins key FDA ok ahead of BMS merger

Aug 19, 2019

The U.S. FDA has approved Celgene's rare bone marrow cancer drug, Inrebic, giving the drugmaker a big regulatory win ahead of its proposed merger with Bristol-Myers Squibb.

Inrebic, a treatment for myelofibrosis, is one of suite of five drugs that Bristol-Myers Squibb regarded as valuable in its deal to buy Celgene. The drug is only the second drug cleared in the U.S. to treat myelofibrosis. Inrebic will carry a black box warning for serious and fatal encephalopathy, including Wernicke’s, a life-threatening neurological condition.

In April, Bristol-Myers Squibb shareholders approved the company’s $74 billion acquisition of rival Celgene, despite activist campaigns to break up the deal.

Read the press release


Don't miss your Daily Dose. Get news like this delivered right to your inbox.